The increased pressure that a hyperbaric oxygen chamber produces oxygenates the fluid of the body directly, without relying on the blood supply. This relieves organ hypoxia much more quickly than ventilation, without stressing lung tissue.
Because high levels of O2 are a potent anti-inflammatory, HBOT also addresses the inflammation in the lungs themselves, which is what is preventing oxygen from reaching the bloodstream in the first place. HBOT also reduces coagulation factors and pro-inflammatory cytokines, effectively addressing the increased clotting and cytokine storm that Covid can create. Dr. Paul Harch notes that in addition to lowering the mortality rate, HBOT averts mechanical ventilation of patients and shortens hospital stays.
Long Covid
We’ve had a great deal of success treating patients with Long Covid, and current studies support our experience:
- Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial
- Oxygen therapy found to improve heart function in patients with long COVID
- Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention
- Hyperbaric oxygen for treatment of long COVID-19 syndrome
- HBOT a potential treatment for those with long COVID-19
- Q&A: Hyperbaric oxygen therapy led to ‘significant cognitive improvement’ in long COVID
Additional Resources